<DOC>
	<DOCNO>NCT02795832</DOCNO>
	<brief_summary>A Randomised , Adaptive Design , Double-Blind ( 3rd Party Open ) , Placebo Controlled , Sequential Group Study Determine Safety , Tolerability , Pharmacokinetics Efficacy Twice Daily Application Topical ZPL-5212372 ( 1.0 % w/w ) Ointment Administered 2 Weeks Adult Healthy Volunteers Patients Moderate Severe Atopic Dermatitis</brief_summary>
	<brief_title>A Study Determine Safety &amp; Efficacy ZPL-5212372 Healthy Subjects Subjects With Atopic Dermatitis</brief_title>
	<detailed_description>This study randomise , adaptive design , double blind ( 3rd party open ) , placebo control , sequential group study healthy volunteer patient moderate severe AD . This study divide 3 separate , sequential cohort : - Cohort 1 ass safety , toleration pharmacokinetics ( PK ) intensive monitor in-patients 7 day dose healthy volunteer . - Cohort 2 ass safety , toleration PK intensive monitoring in-patients 7 day dose moderate severe AD patient . - Cohort 3 ass efficacy , safety , toleration PK out-patients 14 day dose moderate severe AD patient . Subjects receive 1.0 % ( w/w ) ZPL-5212372 match placebo ointment topically , twice daily .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Healthy male female , age 18 55 year , inclusive ( healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Males female age 1865 year inclusive physician document history diagnosis atopic dermatitis least 6 month prior screen . AD diagnose Eichenfield revise criterion Hanifin Rajka . For Atopic Dermatitis Patients : Eczema Area Severity Index ( EASI ) ≥9 &lt; 48 Screening EASI ≥12 &lt; 48 Day 1 . An Investigator 's Global Assessment ( IGA ) score ≥ 3 Screening Day 1 . Atopic dermatitis affect ≥10 &lt; 40 % BSA Screening ≥10 % &lt; 50 % BSA Day 1 . All Subjects : Evidence personally sign date informed consent form , indicate subject inform pertinent aspect study . For Healthy Subjects Evidence history clinically significant haematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Have tattoo cover area skin dose study ointment . Subjects hirsute area skin dose study ointment . Subjects receive treatment investigational drug within 3 month prior screen . For Atopic Dermatitis Patients : AD severity ( EASI &gt; 48 ) subject could comply demand study and/or subject suitable candidate placebocontrolled study . Have concomitant skin disease infection ( e.g . acne , impetigo ) presence skin comorbidities study area dose may interfere study assessment . Have receive phototherapy ( e.g . UVA , UVB PUVA therapy ) , systemic therapy ( e.g . immunosuppressant [ cyclosporine , azathioprine , methotrexate ] , cytostatics ) know suspected effect AD , within 4 week start study . All biologics use within 3 month start study . Have receive systemic corticosteroid ( e.g . oral , intravenous , intraarticular , rectal ) within 4 week start study . Subjects stable maintenance dose ( precede 3 month ) inhale intranasal CS may participate . Patients treat oral antihistamine topical calcineurin inhibitor topical steroid within 7 day start study ; intranasal antihistamine treatment allergic rhinitis acceptable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>